A new booklet for patients, "Managing Rosacea," is now available to National Rosacea Society (NRS) members. The new publication gives tips on what to tell your doctor, describes management options for each subtype and provides guidance on lifestyle and personal care. Members may obtain a free copy -- via postal mail -- by emailing a request to the NRS at rosaceas@aol.com, or by calling 1-888-NO-BLUSH toll free.
Weblog
Posted: 10/30/2007
Although they are normal inhabitants of human skin and cannot be seen, microscopic mites known as Demodex folliculorum may actually be something to blush about, as a new study funded by the National Rosacea Society demonstrated for the first time that these invisible organisms may be a cause or exacerbating factor in rosacea.
Posted: 10/09/2007
Special care may be needed for rosacea patients with severe forms of ocular rosacea (eye symptoms), according to Dr. Sandra Cremers, instructor of ophthalmology at Harvard Medical School. As part of a National Rosacea Society (NRS) research grant, she recently developed a scoring system to identify severe cases of this rosacea subtype, which may affect half of all rosacea patients.
Posted: 08/30/2007
The Summer 2007 Rosacea Review is now online at rosacea.org.
Posted: 08/20/2007
The incidence of rosacea may be higher than widely believed, according to a preliminary study presented at the recent rosacea research workshop, sponsored by the National Rosacea Society (NRS) during the annual Society for Investigative Dermatology meeting. In addition, an ongoing Irish study found similar prevalence rates of subtype 2 (papulopustular) rosacea in both indoor and outdoor workers.
Posted: 08/13/2007
Results of research sponsored by the National Rosacea Society (NRS) on cathelicidins as a causal factor in rosacea were recently published in Nature Medicine, a leading journal on biomedical science. News coverage of the study, including comments from the lead researcher Dr. Richard Gallo and NRS medical advisory board chairman Dr. Jonathan Wilkin, can be viewed here, and an abstract of the article is available here.
Posted: 07/06/2007
New grants are available from the National Rosacea Society (NRS) in 2007 to support research into the potential causes and other key aspects of rosacea, a chronic and often life-disruptive disorder of the facial skin and eyes, now estimated to affect 14 million Americans. The awarding of five research grants totaling $125,000 was announced earlier this year.
Posted: 05/23/2007
The Spring 2007 issue of Rosacea Review is now online at rosacea.org.
Posted: 05/02/2007
New clues to help unlock the mystery of rosacea were identified in a recent study in which researchers used advanced technology to evaluate the skin of patients successfully treated with pulsed dye lasers (PDL) or intense pulsed light (IPL).
Posted: 04/02/2007
The angst and embarrassment of adolescence often come roaring back in adulthood with the red-faced symptoms of rosacea, a widespread but poorly understood facial disorder now estimated to affect 14 million Americans.
Posted: 03/20/2007
As the National Rosacea Society (NRS) marks its 15th anniversary in 2007, we are pleased to report the immense progress that has been made in achieving our mission of improving the lives of people with rosacea through awareness, education and support of medical research on this widespread but poorly understood disorder.
Posted: 02/21/2007
The Winter 2007 issue of Rosacea Review is now available on rosacea.org.
Posted: 02/07/2007
Rosacea Awareness Month to Highlight Wide Prevalence of Chronic Condition
BARRINGTON, Illinois (February 7, 2007) -- More than 14 million Americans are estimated to suffer from rosacea, yet most of them fail to recognize it. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the public to the warning signs of this embarrassing and potentially life-disruptive facial disorder, and to emphasize the importance of seeking medical help.
Posted: 01/15/2007
National Rosacea Society Awards New Grants for Rosacea Research
The National Rosacea Society (NRS) announced that five new studies have been awarded funding as part of its research grants program to advance scientific knowledge of the potential causes and other key aspects of this chronic and potentially life-disruptive disorder that affects an estimated 14 million Americans.
Posted: 01/05/2007
New Study Uncovers the Dark Side of ATP
Researchers have found that one of the most common and hard-working substances in the body may have a Jekyll and Hyde quality in rosacea patients, assuming a darker role when activated by flare-up triggers.
Posted: 10/16/2006
The Fall 2006 issue of Rosacea Review is now available on rosacea.org.
Posted: 08/28/2006
New Study Finds Allergy-like Reaction May Trigger Rosacea Bumps and Pimples
Posted: 07/25/2006
The following announcement was issued by CollaGenex Pharmaceuticals:
FIRST ORAL DRUG FOR ROSACEA
COLLAGENEX PHARMACEUTICALS
INTRODUCES ORACEA™
(doxycycline, USP) capsules 40 mg*
* 30 mg immediate release and 10 mg delayed release beads
Posted: 07/07/2006
The following announcement was issued by the National Women's Health Resource Center:
Do You Live in a Dry Eye Hot Spot?
Posted: 06/14/2006
Trail of Tears May Lead Scientists To First Diagnostic Test for Rosacea
Pages
Contact Us
- Phone:
- 1-888-NO-BLUSH
- Email:
- rosaceas@aol.com
196 James St.
Barrington, IL 60010
Our Mission
The National Rosacea Society is a 501(c)(3) nonprofit organization whose mission is to improve the lives of people with rosacea by raising awareness, providing public health information and supporting medical research on this widespread but little-known disorder. The information the Society provides should not be considered medical advice, nor is it intended to replace
consultation with a qualified physician. The Society does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Rosacea may vary substantially from one patient to another, and treatment must be tailored by a physician for each individual case. For more information, visit About Us.